SCHEMBL30932143

SCHEMBL30932143

CC[C@H](C)[C@H](NC(=O)[C@@H](N)CS)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CS)C(=O)O

nearest known ligand 0.60

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
▸ GLP1R P43220 18/20 0.60
▸ CXCR4 P61073 1/20 0.57
▸ KEAP1 Q14145 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30932144 0.97 GLP1R (0.59) GLP1RKEAP1
SCHEMBL30064553 0.95 GLP1R (0.58) GLP1R
SCHEMBL30183034 0.93 GLP1R (0.55) GLP1RCXCR4
SCHEMBL29434537 0.93 GLP1R (0.57) GLP1R
SCHEMBL29484310 0.93 CTSL (0.53) GLP1RCXCR4KEAP1
SCHEMBL30063985 0.91 GLP1R (0.54) GLP1RCXCR4KEAP1
SCHEMBL30208638 0.91 GLP1R (0.57) GLP1RCXCR4
SCHEMBL29489380 0.90 CTSL (0.53) GLP1RCXCR4KEAP1
SCHEMBL29484311 0.90 GLP1R (0.56) GLP1RKEAP1
SCHEMBL30208639 0.89 GLP1R (0.60) GLP1RCXCR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4622992-A1 COMPSTATIN ANALOGS FOR VECTOR-BASED THERAPY Amyndas Pharmaceuticals US LLC (US) 2025-10-01 — — EP claimed
WO-2024110878-A1 COMPSTATIN ANALOGS FOR VECTOR-BASED THERAPY AMYNDAS PHARMACEUTICALS US LLC (US) 2024-05-30 — — WO claimed
EP-4622992-A1 COMPSTATIN ANALOGS FOR VECTOR-BASED THERAPY Amyndas Pharmaceuticals US LLC (US) 2025-10-01 — — EP disclosed
WO-2024110878-A1 COMPSTATIN ANALOGS FOR VECTOR-BASED THERAPY AMYNDAS PHARMACEUTICALS US LLC (US) 2024-05-30 — — WO disclosed
Send feedback